Combined Haploidentical-Cord Blood Transplantation for Adults and Children



Status:Active, not recruiting
Conditions:Cancer, Blood Cancer, Lymphoma, Hematology, Leukemia
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:1 - Any
Updated:12/2/2017
Start Date:October 9, 2006
End Date:September 2018

Use our guide to learn which trials are right for you!

The primary objective is to assess the rate of engraftment with combined haploidentical-cord
blood transplantation. The secondary objective is to evaluate the incidence and severity of
acute and chronic graft-versus-host disease (GVHD).


Inclusion Criteria:

Patients will be eligible for this study if they have any one of the diseases that are
known to be cured after allogeneic stem cell transplantation.

1. Relapsed or refractory acute leukemia (myeloid or lymphoid)

2. Acute leukemia in first remission at high-risk for recurrence

3. Chronic myelogenous leukemia in accelerated phase or blast-crisis

4. Chronic myelogenous leukemia in chronic phase

5. Recurrent or refractory malignant lymphoma or Hodgkin lymphoma

6. Chronic lymphocytic leukemia, relapsed or with poor prognostic features

7. Multiple myeloma

8. Myelodysplastic syndrome

9. Chronic myeloproliferative disease

10. Hemoglobinopathies

11. Aplastic anemia

Exclusion Criteria:

1. Zubrod performance status > 2

2. Life expectancy is severely limited by concomitant illness

3. Patients with severely decreased LVEF or impaired pulmonary function tests(PFT's)

4. Estimated Creatinine Clearance <50 ml/min

5. Serum bilirubin> 2.0 mg/dl or SGPT >3 x upper limit of normal

6. Evidence of chronic active hepatitis or cirrhosis

7. HIV-positive

8. Patient is pregnant

9. Patient or guardian not able to sign informed consent
We found this trial at
1
site
5801 South Ellis Avenue
Chicago, Illinois 60637
 773.702.1234
University of Chicago One of the world's premier academic and research institutions, the University of...
?
mi
from
Chicago, IL
Click here to add this to my saved trials